Even though drugs, which are tailored to the genetic make-up of a tumor such as HER2 expression, are increasingly being used, not all tumors respond to treatment and options for further targeted treatment is limited for patients that experience relapse of their disease. Here, ERBB2 is linked to neoplasm.